Filing summary
Entity and period: The supplied filing is BioTime, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, not a filing under the name Lineage Cell Therapeutics, Inc. This entity/name mismatch should be confirmed before relying on the summary. Amounts below are in U.S. dollars; financial statement figures are generally in millions unless stated otherwise.
Business context
BioTime described itself as a clinical-stage biotechnology company developing therapies based on pluripotent stem cells and its HyStem cell-delivery platform, alongside cancer diagnostics, research products, databases, and legacy Hextend plasma-volume-expander royalties. It consolidated several majority-owned subsidiaries, including Asterias, OncoCyte, and Cell Cure Neurosciences. Four therapeutic candidates were in human trials: Renevia, AST-VAC1, OpRegen, and AST-OPC1.
Financial performance and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $7.04m | $5.24m |
| Gross profit / gross margin | $5.93m / 84.3% | $4.41m / 84.0% |
| Research and development expense | $42.60m | $37.53m |
| General and administrative expense | $29.13m | $17.56m |
| Operating loss | $65.81m | $50.68m |
| Net loss attributable to BioTime | $46.99m | $36.41m |
| Net loss per common share | $0.59 | $0.55 |
| Net cash used in operating activities | $44.54m | $38.85m |
- Revenue rose 34%, led by grant income ($4.50m, up 37%) and product royalties ($0.72m, up 81%). Grants included recognition of CIRM funding for Asterias. Grant and other non-product revenue were significant contributors; commercial product revenue remained limited.
- Operating expenses increased 30% overall. Management attributed higher R&D costs to clinical and diagnostic development and higher G&A to compensation, legal, consulting, investor-relations, and audit costs.
- Cash and cash equivalents were $42.23m at year-end; available-for-sale securities added $0.75m. Working capital was $34.8m. Total assets were $94.66m and total liabilities $18.21m.
- Cash flow: operating activities used $44.54m, investing activities used $7.44m, and financing activities provided $64.78m; cash increased $12.74m during the year.
- Reported liabilities included $0.32m of related-party convertible debt, $0.32m of promissory notes, and lease obligations; the filing also reports $15.72m of future operating-lease payments. No off-balance-sheet arrangements were reported.
Material changes and notable items
- Compared with 2014, net loss attributable to BioTime widened by $10.58m. The $3.69m gain on the Ascendance investment partly offset operating losses; the gain was non-recurring.
- BioTime raised capital through common-share sales and subsidiary financings. Financing cash flow included $34.12m from common-share issuance, $13.64m from subsidiary share sales, and $11.70m from exercise of subsidiary warrants.
- BioTime distributed approximately 4.75m OncoCyte shares to shareholders at year-end, while retaining a controlling interest. It also formed Ascendance through asset contributions and held a 46.1% interest as of March 2016.
- Stock-based compensation was approximately $11.1m, versus $4.5m in 2014, including accelerated vesting/modification expense related to a former executive.
- FY 2015 quarterly selected data reports Q4 revenue of $1.306m and BioTime-attributable net loss of $13.507m. Elsewhere, the MD&A’s Q4 revenue components total $1.461m. The filing text does not reconcile this difference; verify against the filed financial statements and XBRL.
Outlook, risks, and contingencies
- Management estimated cash, cash equivalents, and available-for-sale securities of $43.0m would fund operations at least through December 31, 2016. This is not a profitability forecast: management stated that additional equity or debt financing would likely be needed, and funding shortfalls could delay or curtail programs.
- Asterias had received $6.6m of a conditional CIRM award of up to $14.3m; further payments depended on milestones. Cell Cure also relied on grant support. OncoCyte could need additional capital in 2016 to establish a CLIA laboratory and prepare commercialization.
- Clinical, regulatory, manufacturing, reimbursement, and intellectual-property risks are substantial. OpRegen enrollment was slowed by an 86% screening-failure rate; Asterias planned further AST-OPC1 dose escalation and a proposed pivotal AST-VAC1 trial remained subject to FDA discussions and design confirmation.
- Management disclosed that FDA-required boxed warnings for hydroxyethyl starch products, including Hextend, cite increased mortality and renal-injury risks in critically ill patients; price competition and these warnings had adversely affected Hextend sales.
- The company reported accumulated losses since inception and no assurance of future profitability. Auditors issued unqualified opinions on the financial statements and internal control over financial reporting; management also assessed disclosure controls as effective.
Most important facts to verify
- Confirm the filing belongs to the intended issuer: the document identifies BioTime, Inc., rather than Lineage Cell Therapeutics, Inc.
- Reconcile the Q4 revenue discrepancy ($1.306m in selected quarterly data versus $1.461m from MD&A components).
- Check the cash runway assumptions, subsidiary-level cash availability, and the timing and conditions attached to grant funding.
- Review dilution exposure from share issuances, outstanding warrants and options, and potential subsidiary financings.
- Track clinical-trial recruitment, safety and efficacy results, FDA feedback, and the effect of competing patents on OpRegen and other programs.